Tag Archives: GSB

Top 5 Tech Stocks To Own Right Now

I’ve said for many years that GoPro Inc. (NASDAQ: GPRO) was never going to be a mass-market product. It’s not exactly a fad, and GoPro stock isn’t a fad stock, either. was a neat little product that found a niche user base. However, there’ve been to other problems which have always dogged GPRO as a company and GPRO stock.

The first problem is that the technology, while cool, never really lent itself to being a quality platform. The HD imagery is great, but I have yet to find a GoPro that delivers really good or useful sound.

Competition and GoPro Stock

The second problem was the inevitable competition and that it would most likely come out of China. Will sure enough, Xiaomi’s Yi Action Cam turned out to be exactly that. Even though it was not released to stateside, it did end up providing significant obstacles for GoPro to expand internationally.

The Xiaomi product is also superior, with higher video and still resolution, enhanced burst photo rate, enhanced video recording capabilities, and enhanced connectivity.

Top 5 Tech Stocks To Own Right Now: GRAVITY Co. Ltd.(GRVY)

Advisors’ Opinion:

  • [By Max Byerly]

    ILLEGAL ACTIVITY WARNING: “Gravity (GRVY) Receives Coverage Optimism Score of 0.17” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at www.tickerreport.com/banking-finance/3382037/gravity-grvy-receives-coverage-optimism-score-of-0-17.html.

  • [By Cooper Creagan]

    For example, if you had taken five minutes to set up a Night Trade on Gravity Co. (Nasdaq: GRVY) in October, you could’ve tripled your money, and then some.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Gravity (NASDAQ:GRVY) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday morning.

Top 5 Tech Stocks To Own Right Now: GlobalSCAPE, Inc.(GSB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Akorn, Inc. (NASDAQ: AKRX) fell 32.7 percent to $13.25 in pre-market trading after Fresenius terminated its merger deal with Akorn.
    Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 15.7 percent to $12.30 in pre-market trading. Subsea 7 confirmed a $7.00 per share proposal to acquire Mcdermott, pending termination of merger agreement with CB&I.
    Myomo, Inc. (NYSE: MYO) fell 9 percent to $3.65 in pre-market trading after rising 11.39 percent on Friday.
    Hasbro, Inc. (NASDAQ: HAS) fell 8 percent to $88.36 in pre-market trading after the company reported weaker-than-expected results for its first quarter on Monday.
    SunPower Corporation (NASDAQ: SPWR) fell 7.1 percent to $9.00 in pre-market trading.
    Endeavour Silver Corp. (NYSE: EXK) shares fell 5.9 percent to $2.88 in pre-market trading after declining 3.16 percent on Friday.
    Mattel, Inc. (NASDAQ: MAT) shares fell 5.5 percent to $12.25 in pre-market trading.
    Valeritas Holdings, Inc. (NASDAQ: VLRX) shares fell 5.1 percent to $2.96 in pre-market trading after rising 76.27 percent on Friday.
    GlobalSCAPE, Inc. (NYSE: GSB) fell 5.1 percent to $3.57 in pre-market trading.
    Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) shares fell 4.1 percent to $49.93 in pre-market trading.
    Oasis Petroleum Inc. (NYSE: OAS) fell 4.1 percent to $9.75 in pre-market trading. SunTrust Robinson Humphrey downgraded Oasis Petroleum from Hold to Sell

Top 5 Tech Stocks To Own Right Now: SuperCom, Ltd.(SPCB)

Advisors’ Opinion:

  • [By Stephan Byrd]

    SuperCom (NASDAQ:SPCB) and CEVA (NASDAQ:CEVA) are both small-cap industrial products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Hanwha Q CELLS Co., Ltd. (NASDAQ: HQCL) is estimated to report quarterly earnings at $0.14 per share on revenue of $438.40 million.
    Remark Holdings, Inc. (NASDAQ: MARK) is projected to report quarterly loss at $0.35 per share on revenue of $19.45 million.
    Athenex, Inc. (NYSE: ATNX) is expected to report quarterly loss at $0.07 per share on revenue of $35.14 million.
    Mazor Robotics Ltd. (NASDAQ: MZOR) is estimated to report quarterly loss at $0.08 per share on revenue of $15.14 million.
    Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is projected to report a quarterly loss at $0.14 per share.
    SuperCom Ltd. (NASDAQ: SPCB) is expected to report quarterly earnings at $0.08 per share on revenue of $9.50 million.
    Lonestar Resources US Inc. (NASDAQ: LONE) is projected to report quarterly loss at $0.04 per share on revenue of $30.68 million.
    Nine Energy Service, Inc. (NASDAQ: NINE) is estimated to report quarterly earnings at $0.1 per share on revenue of $165.76 million.
    VEON Ltd. (NASDAQ: VEON) is projected to report quarterly earnings at $0.05 per share on revenue of $212.00 million.

     

  • [By Shane Hupp]

    Supercom (NASDAQ:SPCB) shares reached a new 52-week high and low during trading on Wednesday . The company traded as low as $1.84 and last traded at $1.92, with a volume of 980 shares traded. The stock had previously closed at $1.92.

  • [By Alexander Bird]

    Here are the top performers from last week…

    Penny Stock Current Share Price Last Week’s Gain
    Aegean Marine Petroleum Network Inc. (NYSE: ANW) $1.83 165.71%
    Radisys Corp. (Nasdaq: RSYS) $1.55 115.68%
    Ascent Capital Group Inc. (Nasdaq: ASCMA) $3.71 43.12%
    Adamis Pharmaceuticals Corp. (Nasdaq: ADMP) $4.36 40.63%
    Tintri Inc. (Nasdaq: TNTR) $0.18 40.49%
    Prana Biotechnology Ltd. (Nasdaq: PRAN) $2.35 39.96%
    Micronet Enertec Technologies Inc. (Nasdaq: MICT) $1.60 39.40%
    Corindus Vascular Robotics (NYSE: CVRS) $1.17 34.40%
    ParkerVision Inc. (Nasdaq: PRKR) $0.70 30.65%
    SuperCom Ltd. (Nasdaq: SPCB) $0.24 30.10%

    While these gains are exciting, they pale in comparison to the profit potential of our top penny stock to buy this week.

Top 5 Tech Stocks To Own Right Now: Turkcell Iletisim Hizmetleri AS(TKC)

Advisors’ Opinion:

  • [By Rich Smith]

    Second verse, same as the first. Last week, shares of Turkish telco Turkcell Iletisim Hizmetleri (NYSE:TKC) got thrown for a 13% loop when the U.S. government announced plans to double tariffs on imports of Turkish steel and aluminum. The Turkish lira took a nosedive in response, rattling the entire Turkish economy — Turkcell included.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Forward Pharma A/S (NASDAQ: FWP) fell 15.2 percent to $3.51 in pre-market trading after surging 88.18 percent on Tuesday.
    Pfenex Inc. (NASDAQ: PFNX) shares fell 15 percent to $5.85 in pre-market trading after the company announced an offering of common stock.
    Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) fell 17.6 percent to $47.75 in pre-market trading after the company reported downbeat results for its first quarter and issued a weak earnings forecast for the second quarter.
    Container Store Group, Inc. (NYSE: TCS) fell 13 percent to $7.15 in pre-market trading after reporting weaker-than-expected earnings for its fourth quarter.
    Ardelyx, Inc. (NASDAQ: ARDX) shares fell 12.1 percent to $4.00 in pre-market trading after reporting pricing of public offering of common stock.
    Boston Scientific Corporation (NYSE: BSX) shares fell 9.8 percent to $27.31 in pre-market trading.
    Turkcell Iletisim Hizmetleri A.S. (NYSE: TKC) fell 6.5 percent to $6.60 in pre-market trading.
    Target Corporation (NYSE: TGT) shares fell 5.8 percent to $71.02 in pre-market trading. Target reported weaker-than-expected earnings for its first quarter, while sales exceeded estimates.
    PBF Energy Inc. (NYSE: PBF) shares fell 5.7 percent to $42.42 in pre-market trading

  • [By Jason Hall, Rich Smith, and Jeremy Bowman]

    But there are plenty of stocks that pay even higher yields that investors should at least entertain buying. We asked three Motley Fool contributors to offer up a compelling dividend stock that’s paying more than Ford, and they came up with a surprisingly diverse list: Pattern Energy Group (NASDAQ:PEGI), L Brands (NYSE:LB), and Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC).

  • [By Lee Jackson]

    Turkcell Iletisim Hizmetleri A.S. (NASDAQ: TKC) was started with an overweight rating at J.P. Morgan. The 52-week trading range for the company’s shares has been $6.33 to $11.29. The consensus price target is $10.94. The shares ended trading on Monday at $6.58.

  • [By Rich Smith]

    Turkish telco Turkcell Iletisim Hizmetleri (NYSE:TKC) became the latest victim of President Donald Trump’s favorite foreign policy tool — the tariff — this morning, falling 13.1% (as of 11:40 a.m. EDT) after the United States announced it would double the amount of tariffs imposed on steel and aluminum imported to the U.S. from Turkey.

Top 5 Tech Stocks To Own Right Now: AVG Technologies N.V.(AVG)

Advisors’ Opinion:

  • [By Shane Hupp]

    FinnCap cut shares of Avingtrans (LON:AVG) to a corporate rating in a research report report published on Monday.

    Shares of LON:AVG opened at GBX 223 ($2.97) on Monday. Avingtrans has a one year low of GBX 174.11 ($2.32) and a one year high of GBX 260 ($3.46).

Hot Blue Chip Stocks To Own Right Now

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 13.0px Verdana; -webkit-text-stroke: #000000} span.s1 {font-kerning: none}

Dow 19,000 has a nice ring to it. And the iconic blue chip stock gauge is edging ever closer to that milestone.

After Mondays record-breaking day, when the Dow Jones industrial average, large-company Standard & Poors 500 stock index, tech-dominated Nasdaq composite and the small-cap Russell 2000 all closed at record levels at the same time for the first time since Dec. 31, 1999, the Dow is on the verge of making more headlines and getting a big shout outon the evening news.

.oembed-asset-link { border-bottom: 1px solid #e1e1e1; } .oembed-link-anchor { display: block; clear: both; } .oembed-link-thumbnail{ float: left; padding: 14px; } .oembed-link-thumbnail img { max-width: 78px; max-height: 60px; display: block; } p.oembed-link-title { font-size: 75%; color: #009BFF; margin: 0 14px; padding-top: 12px; font-weight:normal; text-align: left; line-height: 120%; } p.oembed-link-desc { font-size: 100%; color: #666; font-weight: normal; margin: 0 14px 14px 14px; font-family: ‘Futura Today Light’; text-align: left; line-height: 120%; }

USA TODAY

Hot Blue Chip Stocks To Own Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Shane Hupp]

    These are some of the media headlines that may have effected Accern’s scoring:

    Get Ultragenyx Pharmaceutical alerts:

    Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)

    A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

    A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

  • [By Shane Hupp]

    Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director Matthew K. Fust sold 6,319 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $72.00, for a total value of $454,968.00. Following the transaction, the director now owns 8,750 shares of the company’s stock, valued at $630,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Todd Campbell]

    A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that’s successfully developed drugs for rare diseases.

Hot Blue Chip Stocks To Own Right Now: GlobalSCAPE, Inc.(GSB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Akorn, Inc. (NASDAQ: AKRX) fell 32.7 percent to $13.25 in pre-market trading after Fresenius terminated its merger deal with Akorn.
    Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 15.7 percent to $12.30 in pre-market trading. Subsea 7 confirmed a $7.00 per share proposal to acquire Mcdermott, pending termination of merger agreement with CB&I.
    Myomo, Inc. (NYSE: MYO) fell 9 percent to $3.65 in pre-market trading after rising 11.39 percent on Friday.
    Hasbro, Inc. (NASDAQ: HAS) fell 8 percent to $88.36 in pre-market trading after the company reported weaker-than-expected results for its first quarter on Monday.
    SunPower Corporation (NASDAQ: SPWR) fell 7.1 percent to $9.00 in pre-market trading.
    Endeavour Silver Corp. (NYSE: EXK) shares fell 5.9 percent to $2.88 in pre-market trading after declining 3.16 percent on Friday.
    Mattel, Inc. (NASDAQ: MAT) shares fell 5.5 percent to $12.25 in pre-market trading.
    Valeritas Holdings, Inc. (NASDAQ: VLRX) shares fell 5.1 percent to $2.96 in pre-market trading after rising 76.27 percent on Friday.
    GlobalSCAPE, Inc. (NYSE: GSB) fell 5.1 percent to $3.57 in pre-market trading.
    Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) shares fell 4.1 percent to $49.93 in pre-market trading.
    Oasis Petroleum Inc. (NYSE: OAS) fell 4.1 percent to $9.75 in pre-market trading. SunTrust Robinson Humphrey downgraded Oasis Petroleum from Hold to Sell

Hot Blue Chip Stocks To Own Right Now: (LVMUY)

Advisors’ Opinion:

  • [By Shane Hupp]

    LVMH Moet Hennessy Louis Vuitton (OTCMKTS:LVMUY) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Saturday.

  • [By ]

    French luxury house LVMH SE (LVMUY) stock surged 3.55% in Paris, changing hands at 278.8 after it reported better-than-expected first quarter sales. Organic revenues rose by 13% in the first three months of the year, driven by its fashion and leather goods division.

  • [By Leo Sun]

    At $126, Tiffany trades at about 27 times this year’s earnings estimate — which is a premium valuation relative to the midpoint of its forecast for 12% growth. LVMH (NASDAQOTH:LVMUY), which owns Tiffany’s rival(and Bogliolo’s former employer) Bulgari, trades at just 25 times this year’s earnings — and analysts expect its EPS to jump 16%. Bulgari, like Tiffany, is pivoting away fromits “old world” charms toward edgier marketing campaigns that target younger shoppers.

  • [By ]

    Two years ago, I discussed LVMH (OTCPK:LVMUY) (OTCPK:LVMHF) in another article here on Seeking Alpha. Although I wasnt too impressed with the companys free cash flow yield, I did agree this company deserved a premium valuation. And on top of that, I was expecting its strong growth results to continue in the years ahead. Were now two years later, and LVMH has delivered on every front. Unfortunately the market caught up on that as well, and LVMHs share price has doubled in just two years. And although the LVMH results justify a good performance of the share price, I do think LVMH is getting a little pricey.

Hot Blue Chip Stocks To Own Right Now: Aerojet Rocketdyne Holdings, Inc. (AJRD)

Advisors’ Opinion:

  • [By Rich Smith]

    Aerojet Rocketdyne (NYSE:AJRD) stock lost 12% of its value in the two days after the company reported earnings for the first quarter of 2018 — a miss, and its third such miss in a row, according to data from Yahoo! Finance. Since that report and subsequent drop, however, Aerojet Rocketdyne has come roaring back, recovering all of its losses, and even adding a bit more.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Aerojet Rocketdyne (AJRD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Rich Smith]

    In fact, Boeing and Lockheed Martin look to be two-time winners, as the second largest bump in funding is going to help pay for deep space missions, and to NASA’s Orion crew vehicle and Space Launch System (SLS), which are designed to carry them. Orbital ATK (soon to be absorbed into Northrop Grumman) and Aerojet Rocketdyne (NYSE:AJRD) are other key players on the SLS project. Congress wants to pour an additional $294 million into this program, funding it with $5.1 billion next year.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Aerojet Rocketdyne (AJRD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Medical Stocks To Own For 2018

Marijuana is well on its way to becoming the “norm” in modern America.

Eight states – Alaska, California, Colorado, Maine, Maryland, Massachusetts, Oregon, and Washington – and the District of Columbia have fully legalized possession of small amounts of marijuana for adults’ recreational use. An additional 13 states have decriminalized it. And 29 states, along with Puerto Rico and Guam, now allow the use of medical marijuana.

However, the drug is still classified as an illegal Schedule I substance in the eyes of the federal government.

Top 10 Medical Stocks To Own For 2018: Summer Infant Inc.(SUMR)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of Childrens Placeoutperforming last year before leveling off into a range while mid cap peerCarter’s, Inc (NYSE: CRI) is nearing previous highs againand small cap Summer Infant, Inc (NASDAQ: SUMR) is well below previous highs:

Top 10 Medical Stocks To Own For 2018: Brady Corporation(BRC)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Robert Baird announced on Friday that it has cut its rating on Brady Corp (BRC).

    The firm has downgraded BRC from “Outperform” to “Neutral,” and has given the company a $33 price target. This price target suggests a 8% upside from the stock’s current price of $30.52.

    Analysts see the company’s WPS segment growing faster than expected.

    Brady shares were mostly flat during pre-market trading Friday. The stock is down 9% YTD.

  • [By Michael Flannelly]

    Before the opening bell on Thursday, identification solutions provider Brady Corp (BRC) posted a loss in the fourth quarter, despite a rise in revenues, as it was negatively impacted by a number of charges. However, excluding these charges, the company was able to top Wall Street analysts’ earnings and sales estimates. Nonetheless, BRC shares are plummeting in Thursday’s trading.

    The Milwaukee, Wisconsin-based company posted a loss from continuing operations of $176.2 million, or $3.41 per share, in the fourth quarter, versus last year’s fourth quarter earnings from continuing operations of $20.9 million, or 40 cents per share. Furthermore, Brady posted a net loss of $177.2 million, or $3.43 per share, compared to net earnings of $11.6 million, or 22 cents per share, in the same period a year ago.

    The fourth quarter loss includes non-cash impairment charges of $204.4 million, $15.6 million in restructuring charges, and $4 million in acquisition-related charges. Excluding these charges, Brady Corp said earnings would have been 53 cents per share in the quarter. According to analysts polled by Thomson Reuters, the company was expected to earn an adjusted 51 cents per share in the fourth quarter.

    The company’s fourth quarter sales came in at $309.1 million, up 15% from $269.1 million in sales posted last year. On average, analysts were expecting the company to see $307.13 million in revenues for the quarter.

    Looking ahead, Brady Corp. sees fiscal 2014 earnings coming in between $1.80 and $2.00 per share, below the analysts’ view of $2.30 per share.

    Brady Corp shares were down $1.71, or 5.25%, during early morning trading on Thursday. The stock is up 7.93% year-to-date.

  • [By Mike Deane]

    For the 28th year in a row, Brady Corp (BRC) has increased its dividend payout to investors.

    The Milwaukee, WI-based company increased its quarterly dividend to 19.5 cents from 19 cents, an increase of 2.6%. The annual dividend now stands at 78 cents. The quarterly dividend will be paid on October 31st, 2013 to all shareholders of record on October 10, 2013.

    BRC shares were down 40 cents, or 1.23%, by market close on Wednesday. YTD, the company’s stock is down over 4%.

Top 10 Medical Stocks To Own For 2018: New York & Company Inc.(NWY)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    After looking at this week’s penny stock gainers, we’ll give you that leg up with one of our top-rated penny stocks from our proprietary stock ranking system…

    Penny Stock Current Share Price (March 26) Last Week’s Gain
    Cartesian Inc. (OTCMKTS: CRTN) $0.39 170.69%
    Odyssey Marine Exploration Inc. (Nasdaq: OMEX) $8.76 135.90%
    iFresh Inc. (Nasdaq: IFMK) $8.25 64.64%
    China Auto Logistics Inc. (Nasdaq: CALI) $4.68 47.43%
    National American University Holdings Inc. (Nasdaq: NAUH) $1.20 39.29%
    Document Security Systems Inc. (NYSE: DSS) $1.58 33.91%
    Blonder Tongue Labs Inc. (NYSE: BDR) $0.77 33.90%
    CareDx Inc. (Nasdaq: CDNA) $7.49 29.88%
    Mediwound Ltd. (Nasdaq: MDWD) $5.10 26.51%
    New York & Co. Inc. (NYSE: NWY) $3.37 26.35%

    Don’t Miss This Shot at a $78,000 Windfall: This tiny firm is about to make the entire world wire-free. As its game-changing technology revolutionizes the global power structure, its stock could hand investors a massive return. Learn more…

  • [By Lisa Levin]

    Shares of New York & Company, Inc. (NYSE: NWY) got a boost, shooting up 13 percent to $2.31 as the company posted upbeat quarterly results.

    The GEO Group Inc (NYSE: GEO) shares were also up, gaining 19 percent to $23.27. Following Thursday’s Department of Justice news regarding privately-managed prisons, GEO Group dropped on Thursday, but rebounded Friday after issuing a response to the DoJ.

  • [By Monica Gerson]

    New York & Company, Inc. (NYSE: NWY) shares dropped 42 percent to $1.72 after the company reported downbeat Q1 results and issued a weak Q2 forecast.

Top 10 Medical Stocks To Own For 2018: ZTE Corporation (ZTCOF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The United States has a history of preventing Chinese companies that are even suspected of being state-owned from selling certain products into key industries. Huawei and ZTE (OTCPK:ZTCOF), for example, were under harsh scrutiny for their telecommunications equipment.

  • [By SEEKINGALPHA.COM]

    Chinese telco equipment giant ZTE (OTCPK:ZTCOF) has been actively cooperating and communicating with relevant U.S. government departments in order to reach a conclusion of the investigation related to the compny’s violations of sanctions on Iran.

Top 10 Medical Stocks To Own For 2018: NXP Semiconductors N.V.(NXPI)

Advisors’ Opinion:

  • [By Paul Ausick]

    The offer has two caveats. First, Qualcomm’s bid for NXP Semiconductor N.V. (NASDAQ: NXPI) must either be completed at that price or rejected. Second, Qualcomm may not delay or cancel its scheduled annual meeting set for March 6.

  • [By Jack Foley]

    Furthermore, the NXP Semiconductor (NSDQ:NXPI) acquisition should enable Qualcomm to really become a frontrunner in the lucrative automotive area. There have been rumors that the deal could hit some roadblocks but I see the acquisition eventually going through sometime this year. Qualcomm will want to push its processor business into the automotive market and NXP with its extensive number of loyal distributorsand customers should be able to help here in a big way. Billions are being plowed into theautonomous vehicle market at present and first mover advantage is going to be critical. One would feel that the combined technologies of the Qualcomm/NXP partnership should gain ground here as theIoT phenomenon continues to gain traction. Qualcomm already has a presence here with its Snapdragon processors in some Android Auto IVI systems. For a start, if NXP’sRFCMOS chips (which do away with multi-chip systems) can meaningfully add value to Qualcomm’s current offering in this space, the new partnership could leapfrog a number of competitors in a short span of time, which will be one more positive for QCOM stock.

  • [By Andrew Tonner]

    One of the best ways to invest in broad-based movements such as the IoT is by buying shares in the companies that supply the hardware and infrastructure powering the trend — such asSkyworks Solutions (NASDAQ:SWKS) and NXP Semiconductor (NASDAQ:NXPI). Let’s dig into each company to see what makes them two of the top IoT investments on the market today.

  • [By Sreekanth Anasa]

    Qualcomm (NASDAQ:QCOM) stock price has now fallen below the crucial 20-day, 50-day and 100-day moving averages. Its legal issues have again weighed heavy on QCOM stock of late. QCOM stock has a crucial support at the $52.66 level, which is just below the last closing price (on April 13). Qualcomm stock has not fallen below these levels in 2017.A fall below this level means QCOM stock could drop, moving close to itsone-year lows. However, two popular momentum indicators Bollinger Bands and Relative Strength Index (RSI) indicators suggest that QCOM stock is oversold. The technicals depict mixed scenario for QCOM stock. QCOM stock has lost momentum going into its Q2 earnings, with the stock losing more than 5% in the last 5 trading sessions and is still down more than 10.5% YTD. QCOM stock still makes a good long-term investment, especially with the $47B NXP Semiconductor (NASDAQ:NXPI) acquisition lined up. The smartphone chipset maker’s stock is also named the top dividend stock with insider buying and has adividend yield of 4.27%. Long-term investors with a high-risk appetite might relish buying QCOM stock at such low levels. However, it would be prudent for risk-averse investors to stay on the sidelines till the Q2 earnings, which would give a better picture of Qualcomm’s present legal woes and its future implications.

  • [By Sreekanth Anasa]

    This has the potential to offset the sluggishness in demand of smartphone chips around the world. Also, certain performance benchmarks of Qualcomm’s latest flagship processor 835 are making positive waves. A lot is riding on Qualcomm’s $47B acquisition of NXP Semiconductor (NASDAQ:NXPI), which it plans to complete by the end of the year. This acquisition would open up the high potential IoT segment as well for the smartphone chipmaker. All of these positives have been overshadowed by Qualcomm Inc’s legal troubles, which could hit its licensing business hard. Qualcomm depends heavily on its licensing business to generate bulk of its pre-tax profits. In the most recent fiscal year, Qualcomm’s QTL segment accounted for 78% of its pre-tax profits. The verdicts in the legal issues faced by Qualcomm will not be out anytime soon. These tend to be long drawn courtroom battles, and have cast a spell of uncertainty over Qualcomm’s licensing business.

  • [By Anders Bylund]

    NXP Semiconductors (NASDAQ:NXPI) is knee-deep in a pending merger with sector rival Qualcomm (NASDAQ:QCOM). There was a time when it would have made sense to pick up NXP shares, even if you missed the 25% buyout surge in September.

Top 10 Medical Stocks To Own For 2018: Long Island Iced Tea Corp. (LTEA)

Advisors’ Opinion:

  • [By ]

    Long Island Ice Tea changed its name to Long Blockchain (Nasdaq: LTEA), sending shares 200% higher. It remains to be seen how a beverage maker will create shareholder value from blockchain technology — not that its investors care.

  • [By ]

    5. Blockchain-Related Stocks
    Shorting blockchain-related stocks is an ideal way to not only short bitcoin but also short the entire cryptocurrency craze. Many such stocks exist, such as Riot Blockchain (Nasdaq: RIOT), Long Blockchain (Nasdaq: LTEA), and Longfin (Nasdaq: LFIN). Choose the one that you think is most overhyped and short away!

  • [By Garrett Baldwin]

    William may be right about a sell-off in stocks… in the cryptocurrency space. Over the last week, companies that have billed themselves as blockchain-focused saw their stocks surge. One firm – Long Island Iced Tea changed its name to Long Island Blockchain and watched its stock surge more than triple digits. But today, firms with this exposure are cratering. MGT Capital Investments Inc. (OTCMKTS: MGTI), Long Island Iced Tea Corp. (Nasdaq: LTEA), Riot Blockchain Inc. (Nasdaq: RIOT), and Siebert Financial Corp. (Nasdaq: SIEB) all fell by more than 12% Friday.

Top 10 Medical Stocks To Own For 2018: Forward Pharma A/S(FWP)

Advisors’ Opinion:

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

  • [By Jim Robertson]

    Last Friday, our Under the Radar Moversnewsletter suggested going long on small cap clinical-stage biopharmaceutical stock Forward Pharma A/S (NASDAQ: FWP):

Top 10 Medical Stocks To Own For 2018: Cardtronics, Inc.(CATM)

Advisors’ Opinion:

  • [By Timothy Green]

    Non-bank ATM operator Cardtronics (NASDAQ:CATM) slumped on Friday despite reporting fourth-quarter results that beat analyst estimates on all fronts. The culprit driving the decline may be the company’s 2017 guidance, which calls for a decline in adjusted EPS. At 2:30 p.m. EST, the stock was down about 10%.

Top 10 Medical Stocks To Own For 2018: GlobalSCAPE, Inc.(GSB)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Under the Radar Moversnewsletter suggested going long on small cap sofware stockGlobalSCAPE, Inc (NYSEMKT: GSB):

    As for Globalscape, this one’s a little more straightforward, and obvious. GSB shares pushed up and off of their 200-day moving average line last week, and are making higher highs this week. What you can’t see on the chart is how this has been a pretty reliable pattern for Globalscape for years now. The upper edge of the rising trading range is nearing $6.00, though it would take some time to get there.

Top 10 Medical Stocks To Own For 2018: Insperity, Inc.(NSP)

Advisors’ Opinion:

  • [By Lee Jackson]

    Insperity Inc. (NYSE: NSP) also had a large-scale seller on the desk, and it was another well-known hedge fund. Value Act, which also serves as a director at the company, sold a total of 226,000 shares of the stock at prices that ranged from $71.22 to $72.41. The total for the sale was set at $16 million.Insperity provides an array of human resources and business solutions to enhance business performance for small and medium-sized businesses in the United States. The shares closed the day on Friday at $71.85.